The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and ...

More than 70% of surveyed U.S. ophthalmologists anticipate a fundamentally transformed approach to managing nAMD and DME within the next five years.< ...

Recently released research from Spherix Global Insights provides a timely look at the increasingly competitive and complex treatment landscape for neovascular age-related ...

BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data.

Learn about interactions between Avastin and other medications, supplements, alcohol, and more. You can also find out when to avoid Avastin.

FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

Eylea has become the leading franchise in wet AMD and other ophthalmology markets because of its similar efficacy and more convenient dosing regimen compared with Lucentis and Avastin.

Eylea is a prescription drug used to treat certain eye conditions. Learn about the drug’s dosages, forms, strengths, and more.

Regeneron reported strong Q3 2023 results, driven by the growth of Dupixent and Libtayo, as by Eylea holding up against Vabysmo. Read more on REGN stock here.

EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA ...